Q3 2024 C Rad AB Earnings Call Transcript
Key Points
- C-Rad AB (FRA:24C) maintains a strong financial stability with a solid profitability despite challenges in the EMEA region.
- The company has a comprehensive interoperability portfolio interfacing with major LINAC, Proton, and CT vendors, enhancing its market position.
- C-Rad AB is expanding its global presence, particularly in less mature Southeast Asian markets and Latin America, which strengthens its resilience.
- The APAC region showed strong performance with an 11% increase in order intake and a 43% increase in revenue.
- C-Rad AB has a healthy EBIT margin of 17% and a strong balance sheet with no long-term debt, allowing for future growth investments.
- Order intake for the third quarter declined by 40% from the previous year, falling below expectations.
- Revenue decreased by 10% compared to the same quarter last year, primarily due to lower order intake and backlog conversion timing.
- The EMEA region experienced a significant 77% decrease in order intake, impacted by macroeconomic slowdown and slower decision-making.
- Cash flow was negatively affected by increased receivables related to Proton orders, leading to a decrease in cash at quarter end.
- Concerns were raised about investor confidence following a private presentation that allegedly led to a stock price drop.
Welcome to our Q3 presentation. We had a challenging quarter, but let me kick off by zooming out of it.
Let me briefly take you through C-RAD's long-term strategy and our progress for Q3. C-RAD is active in the field of radiation therapy and approximately half of all cancer patients have radiation therapy as part of their treatment, and we continue to invest in our world-leading products.
C-RAD is in a very strong position with our whole portfolio of interfacing all major LINAC, Proton, and CT vendors. This is our most extensive interoperability portfolio ever.
C-RAD already today, has a global reach, but we are constantly looking into market expansions and we do this step by step. Growing our global presence is strengthening C-RAD's resilience.
And in the third quarter, we continue to see the result of our enhanced focus in the less mature Southeast Asian markets. We are ramping up our investment in Latin America where we had a successful training in connection with ASTRO, the MedTech show ASTRO, for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
